Jessica Hartman
Principal investigator.
Biotech
Built from public records only: federal awards, patents, filings and papers.Is this you? Contact Noair Lab to claim this profile, correct it or hide it.
2019First federal award
$9.4MFederal grants as PI12 awards
0Patents grantedNone matched
0PapersOpenAlex
Federal awards and patents by year
AwardsPatents
12 awards · $9.4M
| Date | Agency | Award | Amount | Company |
|---|---|---|---|---|
| May 1, 2024 | NIH | SBIR Phase II Rapid identification and selection of functional antigen-specific monoclonalantibodies by FcGR-enabled screening on CellRaft Arrays in the CellRaft AIRSystem | $753K | CELL MICROSYSTEMS INC |
| May 17, 2023 | NIH | SBIR Phase II Rapid identification and selection of functional antigen-specific monoclonalantibodies by FcGR-enabled screening on CellRaft Arrays in the CellRaft AIRSystem | $838K | CELL MICROSYSTEMS INC |
| May 17, 2023 | NIH | SBIR Phase II Rapid identification and selection of functional antigen-specific monoclonalantibodies by FcGR-enabled screening on CellRaft Arrays in the CellRaft AIRSystem | $838K | CELL MICROSYSTEMS INC |
| Jul 20, 2021 | NIH | SBIR Phase II Three-dimensional organoid culture using the CellRaft microwell technology | $600K | CELL MICROSYSTEMS INC |
| Jul 20, 2021 | NIH | SBIR Phase I Improving iPSC reprogramming and CRISPR gene editing workflows and efficacy using CellRaft technology | $257K | CELL MICROSYSTEMS INC |
| 2021 | NIH | SBIR Phase I Rapid identification and selection of functional antigen-specific monoclonal antibodies by FcGR-enabled screening on CytoSort Arrays in the CellRaft AIR System | $292K | CELL MICROSYSTEMS INC |
| Dec 31, 2020 | NIH | SBIR Phase I Rapid identification and selection of functional antigen-specific monoclonal antibodies by FcGR-enabled screening on CytoSort Arrays in the CellRaft AIR System | $292K | CELL MICROSYSTEMS INC |
| Aug 1, 2020 | NIH | SBIR Phase II Three-dimensional organoid culture using the CellRaft microwell technology | $634K | CELL MICROSYSTEMS INC |
| Apr 17, 2020 | NIH | SBIR Phase II High Throughput CRISPR/Cas9 cell line generation using the CellRaft Array | $820K | CELL MICROSYSTEMS INC |
| May 1, 2019 | NIH | SBIR Phase II High Throughput CRISPR/Cas9 cell line generation using the CellRaft Array | $1.6M | CELL MICROSYSTEMS INC |
| Apr 8, 2019 | NIH | SBIR Phase II High Throughput CRISPR/Cas9 cell line generation using the CellRaft Array | $813K | CELL MICROSYSTEMS INC |
| — | NIH | SBIR Phase II THE THE PURPOSE OF THE PHASE II PROGRAM IS TO FOCUS ON DEVELOPING A T-CELL ACTIVATION PROTOCOL CONSISTENT WITH REPORTERCELL VIABILITY, DEVELOPING A PR | $1.6M | CELL MICROSYSTEMS INC |
Peer ranks
Federal funding#74
Awards as PI#86
Patents#273
Companies
- CELL MICROSYSTEMS INCLinked by awards · Biotech
Federal awards through Oct 21, 2026 and patents through Oct 20, 2026. Awards come from NIH, NSF and other agency records that name a principal investigator; DoD and NASA contract awards do not, so they are not shown here. Researchers are matched by name and company.